Dermalogica is working harder than ever innovation-wise to solidify its position in the competitive beauty market, ensuring that tip-top skin barrier health remains at the forefront of its offering and messaging.
The 40-year-old Unilever-owned brand is continuing to heavily invest in R&D, especially in the skin care and sunscreen arenas, to target concerns that have been traditionally harder to address, in the hope of putting Dermalogica front-and-centre in beauty shoppers’ minds.
From researching longevity science-focused skin barrier health solutions, to leveraging a plant-based oleosome fusion peptide growth factor to target visible hollowing and loss of density around the eye area, the heritage player continues to innovate in exciting ways.
Not to mention utilising artificial intelligence (AI) design functional peptides with a skin health-first approach to improve the look of pores in a product set to release in 2027.
Dr Bob Bianchini, VP of Technology, Innovation and Development at Dermalogica, lifts the lid on Dermalogica’s R&D plans for 2026/2027 to Cosmetics Business below.
Due to demand, the entry deadline for the Pure Beauty Awards has been extended until 24 July! Don't miss your chance to gain recognition from industry experts and consumers alike. Click here for more information.
How is Dermalogica competing in the competitive skin care space and remaining relevant?
Bianchini: “Dermalogica's approach has always been rooted in skin health first.
While trends come and go, consumers continue to seek products that are backed by functional ingredients, credible science, professional expertise and proven clinical results.
Looking ahead, we see significant opportunities in skin longevity, barrier health, personalised skin care, professional treatments and targeted solutions for concerns that have traditionally been difficult to address.
Our goal is to continue translating advanced skin science into products that deliver meaningful results and support healthier skin over the long term.
Working with our partners at Unilever, who are very deep in skin science, we are excited about our future innovations.
We also do a lot of clinical studies, at least eight-to-ten per year, as we are very deep in terms of our clinical outcomes – key markers, biomarkers, metrics – and the inability to affect things like longevity, barrier health, personalised skin care and targeted solutions.
So, we continue to translate that advanced science, including biotechnology, which is at the forefront.”
Dermalogica's Smart Eye Density Serum
What are your plans for 2026 and 2027 in terms of innovation, and why are these launches crucial?
Bianchini: “Our recent and upcoming innovations reflect the evolving needs of today's consumer.
Smart Eye Density Serum (which launches on 3 August) targets
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Cosmetics Business.
Subscribe now Already a subscriber? Sign in here.
